Last reviewed · How we verify
Pentoxifylline Oral Product
At a glance
| Generic name | Pentoxifylline Oral Product |
|---|---|
| Sponsor | Cedars-Sinai Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Clinical Study to Evaluate The Cardioprotective Effect of Pentoxifylline Against Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients (PHASE2)
- Effect of Pentoxifylline on Preventing Chemotherapy-induced Toxicities in Patients With Breast Cancer (PHASE2)
- Pentoxifylline as an Adjuvant Therapy in the Treatment of Pediatric Pneumonia; A New Perspective of an Old Drug (PHASE4)
- HEMolysis in a Percutaneous Axial Flow LVAD, Effects of Pentoxifylline in a Randomized Controlled Trial (PHASE4)
- Investigational and Comparative Study in the Management of Diabetic Nephropathy (PHASE3)
- Combination Therapy Between Doxycycline, Pentoxifylline, and Nitazoxanide in Sexually Active Men (PHASE2, PHASE3)
- Pentoxifylline Administration in Hemodialysis Patients (EARLY_PHASE1)
- Pentoxifylline Treatment in Acute Pancreatitis (AP) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pentoxifylline Oral Product CI brief — competitive landscape report
- Pentoxifylline Oral Product updates RSS · CI watch RSS
- Cedars-Sinai Medical Center portfolio CI